In summary, we showed that low LLGL2/SLC7A5 mRNA co-expression (LLGL2low/SLC7A5low) was an independent favorable prognostic factor in ERα-positive breast cancer patients, as well as low LLGL2 or low SLC7A5 mRNA expression. The gene discussed is ESR1; the disease is breast carcinoma.